PDLIM7: A Potential Drug Target and Biomarker (G9260)

Target Name: PDLIM7

NCBI ID: G9260

PDLIM7

PDLIM7: A Potential Drug Target and Biomarker

The protein PDLIM7 (Proteasome-Defined Limitry-Modifier-7) is a key regulator of the proteasome, a complex protein machine that helps to break down and process large proteins into smaller ones. PDLIM7 is a 22-kDa protein that is expressed in most tissues and cells of the body. It is involved in the regulation of a wide range of cellular processes, including cell survival, apoptosis (programmed cell death), and inflammation.

The discovery of PDLIM7 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases.

PDLIM7 as a Drug Target

PDLIM7 has been shown to play a critical role in the regulation of cellular apoptosis, which is the process by which cells suicideally destroy themselves when they are no longer needed. PDLIM7 is involved in the formation of the apoptotic complex, which is composed of several proteins that work together to ensure the efficient and timely execution of cell death.

PDLIM7 has also been shown to play a role in the regulation of inflammation, which is a critical immune response to infection and injury. PDLIM7 has also been shown to regulate the production of pro-inflammatory cytokines, which are important mediators of inflammation.

PDLIM7 as a Biomarker

PDLIM7 has also been shown to be a potential biomarker for a variety of diseases. For example, PDLIM7 has been shown to be downregulated in a variety of cancer tissues, which suggests that it may be an attractive target for cancer therapies. Additionally, PDLIM7 has has been shown to be involved in the regulation of cellular senescence, which is the process by which cells age and eventually die. This suggests that PDLIM7 may be an attractive target for therapies aimed at slowing or reversing cellular aging.

PDLIM7 is also expressed in the brain, and it has been shown to be involved in the regulation of a variety of cognitive processes, including memory and learning. This suggests that PDLIM7 may be an attractive target for therapies aimed at enhancing cognitive function in aging populations.

Conclusion

PDLIM7 is a protein that has significant implications for a variety of cellular processes, including cell survival, apoptosis, and inflammation. Its involvement in these processes makes it an attractive target for new therapies. The potential of PDLIM7 as a drug target and biomarker suggests that it may be a valuable tool in the development of new treatments for a variety of diseases. Further research is needed to fully understand the role of PDLIM7 in cellular processes and its potential as a drug and biomarker.

Protein Name: PDZ And LIM Domain 7

Functions: May function as a scaffold on which the coordinated assembly of proteins can occur. May play a role as an adapter that, via its PDZ domain, localizes LIM-binding proteins to actin filaments of both skeletal muscle and nonmuscle tissues. Involved in both of the two fundamental mechanisms of bone formation, direct bone formation (e.g. embryonic flat bones mandible and cranium), and endochondral bone formation (e.g. embryonic long bone development). Plays a role during fracture repair. Involved in BMP6 signaling pathway (By similarity)

The "PDLIM7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDLIM7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets